Open AccessGlycA, a novel inflammatory marker, is associated with subclinical coronary disease
Author(s) -
Martin Tibuakuu,
Oluwaseun E. Fashanu,
Di Zhao,
James D. Otvos,
Todd T. Brown,
Sabina A. Haberlen,
Eliseo Güallar,
Matthew J. Budoff,
Frank J. Palella,
Jeremy Martinson,
Akintunde O. Akinkuolie,
Samia Mora,
Wendy S. Post,
Erin D. Michos
Publication year - 2019
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0000000000002079
Subject(s) - medicine , serostatus , coronary artery disease , multicenter aids cohort study , subclinical infection , population , cohort , cardiology , coronary atherosclerosis , human immunodeficiency virus (hiv) , viral load , gastroenterology , immunology , antiretroviral therapy , environmental health
GlycA, a novel NMR biomarker of inflammation, has been associated with incident cardiovascular disease (CVD) in the general population, but its association with CVD among HIV-infected individuals is unknown. We examined the associations between GlycA and subclinical coronary plaque among HIV-infected and HIV-uninfected men participating in Multicenter AIDS Cohort Study (MACS).